Time New York: Wed 23 Aug 13:40 pm  |  Save 15% on H&R Block Online

  
caticonslite_bm_alt

BioTelemetry (BEAT) Acquires LifeWatch for $280 Million

Zacks

BioTelemetry Inc. BEAT recently announced the acquisition of LifeWatch AG in a deal valued at about $280 million. With this buyout, BioTelemetry enhanced its position in the wireless medicine space, enlarging its product profile and customer base in the cardiac monitoring and diagnostic services space.

Stock Performance

The price performance of BioTelemetry has been favorable in the last three months. The stock has gained 12.79%, outperforming the Zacks classified Medical Services sub-industry’s gain of almost 6.78%. The current level compares favorably with the S&P 500’s return of 4.93% over the same time frame.

The estimate revision trend for the current year has been positive in the last two months. Two estimates moved south against six movements in the opposite direction. This, together with a solid long-term earnings growth rate of 29.7%, instills our confidence in the stock.


Coming back to the news, management expects that the acquisition will yield significant synergies over the next 12–18 months. Both companies make products which are utilized for remotely monitoring cardiac care patients.

Headquartered in Zug, Switzerland, LifeWatch is a leading healthcare technology and solutions company, specializing in advanced digital health systems and wireless remote diagnostic patient monitoring services.

Going forward, BioTelemetry has been gaining prominence of late on expanded payer coverage and with the introduction of innovative products. Furthermore, we note that BioTelemetry as of Mar 31, had a strong financial position with more than $25 million in cash. The company posted stellar first-quarter revenue of $56 million, up 15% on a year-over-year basis. Meanwhile, the company expects double-digit revenue growth and expects an approximate 23% EBITDA return for fiscal 2017. For the quarter ending Jun 30, the company expects revenue growth of over 10%, or $58 million to $59 million and an EBITDA return of about 21%.

Headquartered in Conshohocken, PA, BioTelemetry provides cardiac monitoring services, and cardiac monitoring device manufacturing.

Zacks Rank & Key Picks

Currently, BioTelemetry carries a Zacks Rank #3 (Hold).

A few better-ranked medical stocks are Mesa Laboratories, Inc. MLAB, Edwards Lifesciences Corp. EW and Align Technology, Inc. ALGN. Notably, Mesa Laboratories and Edwards Lifesciences sport a Zacks Rank #1 (Strong Buy), while Align Technology carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Mesa Laboratories has a positive earnings surprise of 2.84% for the last four quarters. The stock has added roughly 9.1% over the last three months.

Edwards Lifesciences has a long-term expected earnings growth rate of 15.2%. The stock has gained around 21.3% over the last three months.

Align Technology has an expected long-term adjusted earnings growth of almost 24.1%. The stock has added roughly 32.1% over the last three months.

Today's Stocks from Zacks' Hottest Strategies

It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 – Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.

And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 – Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation. See Them Free>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.

Zacks Investment Research
<-- You can share this post with your network,
or give us your opinion and leave a comment.
Be sure to check our RSS feeds for updates.